Showing results (2191-2200 of 2,287) with videos related to

Sort By:
Pageof 229
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant gliomaJennifer A Quinn, James Pluda, M Eileen Dolan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2005
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study resultsDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
The Lancet. Healthy Longevity|January 14, 2022
Grand Challenges in global eye health: a global prioritisation process using Delphi methodJacqueline Ramke, Jennifer R Evans, Esmael Habtamu, et al.
Acta Psychiatrica Scandinavica|March 4, 2022
Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorderAnna L Wrobel, Ole Köhler-Forsberg, Louisa G Sylvia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Irinotecan therapy in adults with recurrent or progressive malignant gliomaH S Friedman, W P Petros, A H Friedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomasDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
British Journal of Clinical Pharmacology|October 4, 2018
Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP)Edward C Hsiao, Maja Di Rocco, Amanda Cali, et al.
Biological Psychiatry|September 11, 2007
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phasesMartin B Keller, Madhukar H Trivedi, Michael E Thase, et al.
Pageof 229